公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!

抑制剂描述:

产品名称:VX-809

产品别名:见爱必信官网

英文别名:VX-809

靶点:CFTR

CAS:936727-05-8

纯度:>98%

外观:见爱必信官网

保存方法:Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.

描述:

VX-809 (Lumacaftor)通过促进突变型CFTR(F508del-CFTR)的成熟,从而纠正常见于囊性纤维化的CFTR突变,EC50为0.1 μM。VX-809在雌激素受体(ER)水平上起作用的行为,使一部分F508del-CFTR采取正确折叠的方式,退出ER,转移到细胞表面,正常起作用。VX-809作用于表达 F508del-CFTR的Fischer 大鼠甲状腺 (FRT)细胞, VX-809显著提高F508del-CFTR突变,提高7.1 倍,EC50为0.1 μM, 且增强F508del-CFTR调节的氯离子运输,提高5 倍, EC50 为0.5 μM, 而VRT-768作用时具有更高的EC50 值,EC50分别为7.9 μM 和 16 μM。VX-809 (3 μM)作用于表达F508del-CFTR的HEK-293细胞,提高ER中的F508del-CFTR,提高6倍。

溶解性:DMSO : 50 mg/mL (110.52 mM; Need ultrasonic)

体外研究:

In fischer rat thyroid (FRT) cells, VX-809 improves F508del-CFTR maturation by 7.1±0.3 fold (n=3) compared with vehicle-treated cells (EC50, 0.1±0.1 μM; n=3) and enhances F508del-CFTR-mediated chloride transport by approximately fivefold (EC50, 0.5±0.1 μM; n=3). At VX-809 concentrations greater than 10 μM, the response is reduced, resulting in a bell-shaped dose-response relationship with an IC50 of approximately 100 μM. VX-809 is orally bioavailable in rats and achieved in vivo plasma levels significantly above concentrations required for in vitro efficacy. VX-809 produces a concentration-dependent increase in the HRP luminescence signal after incubation with cells at 37°C or 27°C in both cell lines, with a similar EC50 value of approximately 0.3 μM. In F508-HRP CFBE41o- cells at 37°C, VX-809 increases the signal maximally to approximately 250 luminescence arbitrary units (a.u.) over the DMSO control baseline of approximately 60 a.u., representing an approximately 4-fold signal increase. Similarly, with the R1070W-HRP CFBE41o- cells, VX-809 increases the signal maximally to approximately 220 a.u. over the DMSO control baseline of approximately 85 a.u., representing an approximately 2.5-fold signal increase. Therefore, both cell lines produced robust signals with a good dynamic range for high-throughput screening.

体内研究:Oral dosing of 1 mg/kg VX-809 in male Sprague-Dawley rats results in a Cmax of 2.4±1.3 μM with a t1/2 of 7.7±0.4 h (mean±SD; n=3), indicating that that VX-809 is orally bioavailable and able to reach plasma levels that significantly exceeded EC50s for F508del-CFTR correction.

产品信息订购:

产品更多信息请进入爱必信网站咨询